Atlas Trials

Linperlisib Combined With EZH2 Inhibitor in Relapsed/Refractory Peripheral T-cell Lymphoma (PTCL)

Clinical trial NCT06712173 · NOT_YET_RECRUITING

Trial details

NCT number
NCT06712173
Sponsor
Institute of Hematology & Blood Diseases Hospital, China
Status
NOT_YET_RECRUITING
Phase
Phase 1
Study type
INTERVENTIONAL
Peripheral T Cell Lymphoma
Start date
2024-12-01
Primary completion
2025-09-30
Enrollment
33

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.